Akorn Inc. Opens First International Office

02-Jun-2005

Akorn, Inc. announced the appointment of Vandana J. Sonavaria, Ph.D. as Director, International Compliance and regulatory affairs. Dr. Sonavaria will establish the company's first international office in Pune, India on the campus of Serum Institute of India Ltd (Serum), with whom Akorn has entered into an exclusive drug development and distribution agreement.

Dr. Sonavaria will be responsible for quality, cGMP and CFR compliance and regulatory affairs for the pipeline of new ANDA products, which the company expects to market as a result of agreements with Serum, FDC Limited and Strides Arcolab Limited.

Since 2004, Dr. Sonavaria was Director, Product Development, R&D for Sicor Pharmaceuticals Inc., where she provided leadership and technical support for the company's parenteral, biological and oncolytic ANDA submissions. From 2000 to 2004, she served as Associate Director, Product Development, R&D at Sicor.

From 1997 to 2000, Dr. Sonavaria served as Principal Scientist at American Pharmaceutical Partners (then Fujisawa USA, Inc.), where she led multiple projects related to the scale up and manufacture of stability and validation batches for new products. She joined Fujisawa as Senior Scientist in 1994.

Dr. Sonavaria holds both a Ph.D., and M.S., in Pharmaceutical Sciences and Industrial Pharmacy from Massachusetts College of Pharmacy, Boston, and a B.B. in Pharmacy from C.U. Shah College of Pharmacy, Bombay, India.

Other news from the department people

More news from our other portals

So close that even
molecules turn red...